Introduction
The Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage MultiArm Randomised Controlled Trial (STAMPEDE) started recruiting in October 2005. It recruits men with either newly diagnosed metastatic (M1), high-risk localised, or node-positive (N+) prostate cancer (PCa). The trial tests the addition of further treatments to androgen deprivation therapy (ADT), including docetaxel, zoledronic acid, celecoxib, abiraterone, enzalutamide, and (among newly diagnosed M1 patients only) radiotherapy, using a multiarm, multistage design. Research arms have recruited at overlapping times, but the control arm has been consistently ADT alone and recruited throughout [1] .
PCa is the second most common cancer worldwide among men. With newer licensed therapies that prolong survival in patients relapsing with metastatic castrateresistant prostate cancer (mCRPC) [2] [3] [4] [5] [6] [7] [8] [9] and the increasingly widespread use of prostate-specific antigen (PSA) testing, men with M1 disease may have lower disease burden at diagnosis than in the past. In this era of PSA testing and effective therapies for patients with mCRPC, there are limited, contemporary, long-term data on the natural history of newly diagnosed patients receiving ADT alone. Data from older studies tend to quote median overall survival (OS) times of 30-36 mo [2, 3, [10] [11] [12] and a median OS of around 18 mo in the castrate-resistant setting. Given recent changes to the management paradigm of mCRPC, it is timely to explore current survival outcomes and treatment standards. Now the largest therapeutic randomised controlled trial in PCa, the STAMPEDE trial's control arm provides valuable data on survival outcomes, prognostic factors, and subsequent treatments for a prospective cohort of men with newly diagnosed M1 disease receiving standard-of-care therapy. This paper aims to describe survival outcomes for such men and considers these in the context of similar groups in older trials. We also investigate factors associated with prognosis and describe subsequent treatments received following disease progression.
2.
Patients and methods
Overall trial recruitment and eligibility
Patients were recruited to the STAMPEDE trial from >100 sites across the United Kingdom and Switzerland. To be eligible, patients must have PCa that was either high-risk, newly diagnosed, nonmetastatic, node-negative (N0) disease, newly diagnosed M1 or N+ disease, or disease (previously treated with radical surgery and/or radiotherapy) that was rapidly relapsing at the time of randomisation. The patients must have been intended for treatment with long-term ADT started no longer than 12 wk prior to randomisation, if at all. Baseline investigations must have been completed prior to randomisation, including computed tomography (CT) scan or magnetic resonance imaging (MRI) of the pelvis and abdomen, bone scan or equivalent (eg, whole body MRI; chest radiograph, if the chest was not included in the CT scan; or MRI), electrocardiogram, and PSA test.
There were no age restrictions, and patients had to be fit for chemotherapy and have no significant cardiovascular history. 
Population of interest
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Key trial eligibility criteria: High-risk, newly diagnosed, nonmetastaƟc, node-negaƟve disease or Newly diagnosed metastaƟc or node-posiƟve disease or Previously treated with radical surgery and/or radiotherapy, now relapsing and Fit for all protocol treatment and follow-up Allocated to control arm n = 1716
Allocated to research arms n = 3556
MetastaƟc n = 976
NonmetastaƟc n = 740
Randomised by 7-January-2014, N = 5272
Newly diagnosed within 6 mo before randomisaƟon, n = 917
Included in these analyses n = 917
Diagnosed >6 mo prerandomisaƟon n = 59
Fig. 1 -Patient selection process for this newly diagnosed M1 controlarm cohort analysis.
either orchidectomy or luteinising hormone-releasing hormone agonists or antagonists, with or without long-term oral antiandrogens. Treatment after disease progression was at the discretion of the consulting clinician.
Data collection
Baseline data included patient demographics, metastatic sites, regional lymph node status, primary tumour stage, and diagnosis date. Details of disease progression and subsequent treatments were obtained from progression forms. Details of cardiovascular and acute renal events were obtained from follow-up and serious adverse event forms. The protocol can be found online [13] . The trial was registered both on clinicaltrials.gov as NCT00268476 and on controlled-trials.com as ISRCTN78818544, had the relevant regulatory and ethics approval, and all patients gave written, informed consent.
Outcome measures
The trial's definitive and intermediate primary outcome measures were overall survival (OS) and failure-free survival (FFS) [14] ; these outcome measures formed the primary focus of this cohort analysis. Survival was defined as time from randomisation to death from any cause. FFS was defined as time from randomisation to evidence of at least one of the following: biochemical failure; progression either locally, in lymph nodes, or in distant metastases; or death from PCa.
Biochemical failure was defined as failing at diagnosis (PSA nadir >50% of the last pretreatment PSA level), 50% increase above nadir (PSA nadir at least 50% lower than the last pretreatment PSA level but remaining >4 ng/ml), or either a 50% increase from nadir or PSA level >4 ng/ml (PSA nadir <4 ng/ml). The PSA nadir was taken as the lowest PSA value reported in the first 24 wk after randomisation. 
Statistical analyses
Analyses were performed using Stata v13 (StataCorp LP, College Station, TX, USA) using standard survival-analysis methods. Kaplan-Meier estimates were used to produce survival curves. Univariate and multivariate Cox models explored the impact of predefined subgroups.
Time-to-event analyses were calculated from randomisation to the outcome of interest, with those not experiencing the event censored at time of last contact, except PSA nadir, which used a landmark at 26 wk postrandomisation to allow for the nadir to be calculated. The impact of PSA nadir could not be examined for men with events or withdrawal of consent prior to 26 wk or insufficient data up to 26 wk. Median follow-up was determined through reverse censoring on death.
Results
The cohort selection process is shown in Figure 1 . Of 5272 eligible patients randomised to the trial from October 2005 to January 2014, 1716 patients were allocated to the control arm. Of these, 917 men had metastatic PCa newly diagnosed within 6 mo before randomisation. These 917 men form the cohort described here and constitute 17% of patients joining the trial. The data set was frozen in January 2014, with median follow-up of 20 mo (interquartile range [IQR]: 6-37) and total follow-up for all patients of 1449.7 yr. 2) . Tables 2 and 3 show the relative impact of prognostic factors on FFS and OS, respectively. In univariate models, metastases grouping was associated with both FFS and OS, as were primary tumour stage, initial Gleason sum score category, age group, and WHO performance status. Figures 3 and 4 present Kaplan-Meier curves by metastases grouping, WHO performance status, initial Gleason sum score category, and age group, for FFS and OS, respectively. Presence of bone metastases was associated with lower 2-yr OS in men with soft tissue metastases, from 85% to 60% (hazard ratio: 3.42; 95% CI, 1.96-5.97). Higher PSA level before starting ADT and higher primary tumour stage showed evidence of worsened FFS. In the subset of patients with bone-only metastases, there was no evidence that regional lymph node involvement affected either FFS or OS. In the landmark analysis of 457 patients with sufficient followup and event free at 26 wk, higher PSA nadir showed evidence of worsened FFS; this was similar for OS in 644 patients with sufficient follow-up and alive at 26 wk.
Patient cohort
In multivariate models, presence of bone metastases regardless of soft tissue metastases, worse WHO performance status, higher or unknown initial Gleason sum score category, and younger age at randomisation showed strong evidence of both worsened FFS and OS after adjusting for the other factors. Worsening primary tumour stage and higher PSA level before starting ADT were both associated with poorer FFS outcomes but not OS.
3.3.
Cardiovascular and acute renal events Cardiovascular causes were reported as primary cause of death (COD) for seven patients; none had renal causes reported as primary COD, although it was reported as secondary COD for 11 patients (10 for whom PCa was primary COD). With regard to worse toxicity grade reported up to disease progression, seven patients had G3-4 cardiac disorder and nine patients had G3-4 renal toxicity (Table 4) .
Subsequent treatments and outcomes from progression
Supplementary Figure 1a shows the most frequent series of subsequent therapies reported at progression (given either in combination or independently over time), which were bisphosphonate, chemotherapy, and abiraterone; no further detail is reported here. Supplementary Figure 1b shows time to subsequent therapy from first FFS event; all crossover/ subsequent treatments after initial treatment failure were given at the investigator's discretion. Of 502 patients relapsing so far, 50% started chemotherapy within 16 mo Fig. 2 -Failure-free and overall survival for newly diagnosed M1 patients in the STAMPEDE trial control arm. FFS = failure-free survival; IQR = interquartile range.
after an FFS event; other subsequent therapies, including bisphosphonate and abiraterone, were reported starting after a longer time.
Of 502 patients with an FFS event, 230 died; median follow-up time from FFS event was 22 mo. Median survival from FFS event was also 22 mo, with 46% (95% CI, 40-51) alive 2 yr after the first FFS event.
Discussion
Within this cohort of metastatic, newly diagnosed PCa patients, treated only with ADT, we found median FFS to be 11.2 mo for the whole cohort from study entry, whereas median OS was 42.1 mo. For FFS and OS, respectively 29% and 72% of patients were event free at 2 yr. Factors prognostic of worsened outcome included presence of bone metastases with or without soft tissue metastases, worse WHO performance status, higher or unknown initial Gleason sum score category, and younger age at randomisation, for both FFS and OS. Worsening primary tumour stage and higher PSA level before starting ADT were associated with worsened FFS only. PSA nadir at 24 wk was pertinent in the landmark analysis of patients who were still responding to ADT at that time. Subsequent therapies reported soonest on disease progression were largely chemotherapy based. # Analyses for PSA nadir were based on a landmark start time for patients of 6 mo; therefore, 2-yr survival is survival at 18 mo from the landmark.
These data suggest a relative improvement in survival outcomes compared to older literature, but survival from presentation with M1 PCa remains disappointing (Fig. 2) [11, 12, 15] , shorter than in the control arms of the Androgen-Deprivation Therapy Alone or with Docetaxel in Noncastrate Metastatic Prostate Cancer Trial (GETUG-15; 54 mo) and SWOG Phase III Trial Experience S9346 (49 mo) [12, 16] , and similar to the 42 mo presented for the control arm in the ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) [17] . Inclusion criteria were not identical for these trials.
Data collected within our cohort allowed examination of prognostic factors at presentation. Of particular interest was the lack of detectable effect of regional lymph node positivity as compared to distant node positivity on overall prognosis. In particular, these data underscore the value of CI = confidence interval; HR = hazard ratio; NA = not applicable; OS = overall survival; PSA = prostate-specific antigen; WHO = World Health Organization. * Cox models adjusted for age at randomisation as relevant. y Cox models adjusted for all other variables unless marked as NR (not relevant). § WHO performance status is defined as: 0: normal activity without restriction; 1: strenuous activity restricted, can do light work; 2: up and about >50% of waking hours, capable of self-care. # Analyses for PSA nadir were based on a landmark start time for patients of 6 mo; therefore, 2-yr survival is survival at 18 mo from the landmark. Age at randomisation, yr Age at randomisation, yr 
soft tissue imaging in patients presenting with a positive bone scan, as concurrent presence of soft tissue metastasis (mainly lymph nodes), in addition to bone metastases, worsened 2-yr OS from 75% to 60%. Although uncommon, soft tissue-only metastases had the most favourable outcome, with 85% 2-yr OS. These effects were similar whether the small proportion with visceral metastases was omitted or included.
The finding that median OS is more than double the median FFS demonstrates that the mCRPC phase now makes up the majority of the survival time rather than being a short terminal phase with limited treatment options. This is consistent with the growing number of available therapies for mCRPC. Indeed, our prospectively collected data were drawn from men treated in the so-called docetaxel era. Several new agents have been licensed for mCRPC since 2002, including therapies such as docetaxel [2, 3] , cabazitaxel [4] , and abiraterone [5, 7] ; there are other new agents such as enzalutamide [6] , radium-223 [8] , and sipuleucel-T [9] with positive results but limited availability so far in this cohort. In addition, there have been improvements in supportive care, particularly for men with bony metastatic PCa, with licensing of zoledronic acid [18, 19] and denusomab [20, 21] . Attitudes in managing men with mCRPC have shifted from care with palliative intent to active treatment using therapies improving survival and reducing morbidity.
The cohort of patients presented here should access these new salvage options. Abiraterone has only been widely available since 2011, with a licence extension to the prechemotherapy population in 2013; hence, we would expect to see changes in patterns of abiraterone use as the data mature. With a similar extension of the licence to pre-docetaxel patients pending for enzalutamide, this use is also likely to change. Likewise, although all patients entering the trial were fit for chemotherapy, the reported median time from relapse to chemotherapy is estimated at 16 mo, with time to the upper quartile not yet reached, suggesting a significant proportion of patients will never receive chemotherapy. As drugs such as abiraterone (also an experimental arm in the main trial) move into wider practice, we shall examine the impact of salvage strategies on OS (Supplementary Fig. 1 ).
The main strengths of our cohort include patients being from multiple centres with consistent, prospectively collected data and uniform standard-of-care treatment. However, there are limitations. First, our substantive cohort was drawn from the control arm of a clinical trial, inevitably applying eligibility restrictions. This cohort was likely more fit-due to exclusions for cardiovascular disease, men had to be sufficiently fit to potentially receive chemotherapy (to March 2013) and to have no significant cardiovascular history [22] to potentially receive celecoxib (to April 2011 [22, 23] -and younger than unselected men with newly diagnosed metastatic PCa (median age was around 10 yr below the median of the PCa population). Use of upfront docetaxel may have deterred older patients from entering the trial and may be one of the explanations for the low median age of this cohort; age is often used inappropriately as a surrogate for fitness. As our cohort may be less likely to die from intercurrent illness, particularly cardiovascular, PCa was the leading cause of death.
Second, our analyses are timed from randomisation rather than diagnosis, making comparability against other cohorts difficult, particularly single-centre series likely to start from diagnosis. Patients were only eligible for STAMPEDE if they were on ADT for no longer than 12 wk before randomisation; most patients had been exposed to 6-8 wk of ADT before randomisation.
Third, median follow-up within this cohort is only 20 mo; recruitment was ongoing when this data set was frozen; however, more than one-half of patients reported a FFS event (502 of 917 men). Fourth, there may be underreporting of treatments used after first progression, particularly for treatments given later in the patient pathway.
The prognostic variables used within the multivariate models were all pre-specified and we feel we used the best disease predictors that we could identify in the data set available. We acknowledge that the multivariate model is likely incomplete. Laboratory values (including haemoglobin, albumin, serum creatinine, and alkaline phosphatase levels) were requested, but the completeness of the necessary data to standardise these variables was lower than we wished to accept and we wanted to avoid imputation of missing values. These are likely important measures, previously identified as prognostic factors in the Halabi nomogram, albeit in CRPC patients [24] . We did not collect data on bone pain [25] . We anticipate that WHO performance status (which we included in our analysis) may already reflect the impact on general health from these other variables.
Although using data from a trial's control arm has limitations, there is a need for a population-based prospective cohort study in this population to address questions prospectively. No such study has been reported, and construction of one would be at great financial cost while taking many years to provide reliable long-term data. The control arm of a high recruiting trial, such as STAMPEDE, therefore provides high-quality prospective data for patients receiving standard-of-care therapy in a hormone-naïve setting. It makes efficient use of the wealth of data collected for the trial, incurring no extensive additional costs and simultaneously providing treatment safety and efficacy answers. Also, our eligibility criteria were typical of clinical trials in this therapy area, so these data are particularly relevant to planning future studies in this population.
Conclusions
Survival outcomes in this large, multicentre cohort of men with metastatic, newly diagnosed disease were shown to have improved compared to previous reports in the literature, although survival still remains disappointing for this patient population. Subsequent therapies primarily consisted of docetaxel alone or with other therapies. Factors independently prognostic of shorter time to both disease progression and death included younger age, presence of bone metastases with or without soft tissue metastases, a Gleason score category 8, and a WHO performance status worse than zero. It is apparent that survival outcomes in this setting still need to be greatly improved. The STAMPEDE trial will prospectively report on eight treatment combinations randomised against standard of care over 15 yr. Comparative survival results should start to emerge from 2015.
The preliminary results of this study were presented at the American Society of Clinical Oncology annual meeting
